1-11 of 11
Sehoon Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1767: Targeting prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature

Khalid A. Mohamedali, Zhi Gang Li, Michael W. Starbuck, Xinhai Wan, Jun Yang, Sehoon Kim, Weihe Zhang, Nora M. Navone, Michael G. Rosenblum
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1767.
https://doi.org/10.1158/1538-7445.AM2011-1767
Published: 15 April 2011
View articletitled, Abstract 1767: Targeting prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature
Journal Articles

Abstract 711: VEGF121/rGel inhibits prostate cancer-induced osteoblastogenesis by targeting osteoblasts and tumor neovasculature

Khalid A. Mohamedali, Zhi Gang Li, Michael W. Starbuck, Xinhai Wan, Jun Yang, Sehoon Kim, Wendy Zhang, Nora M. Navone, Michael G. Rosenblum
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 711.
https://doi.org/10.1158/1538-7445.AM10-711
Published: 15 April 2010
View articletitled, Abstract 711: VEGF121/rGel inhibits prostate cancer-induced osteoblastogenesis by targeting osteoblasts and tumor neovasculature
Journal Articles

Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies

Yu Cao, James D. Marks, John W. Marks, Lawrence H. Cheung, Sehoon Kim, Michael G. Rosenblum
Journal: Cancer Research
Cancer Res (2009) 69 (23): 8987–8995.
https://doi.org/10.1158/0008-5472.CAN-09-2693
Published: 30 November 2009
View articletitled, Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies
Open the PDF for Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies in another window
Includes: Supplementary data
Journal Articles

Abstract #3628: Development and characterization of human anti-CEA single-chain immunotoxins containing rGel: design improvements for greater efficacy

Sehoon Kim, Lawrence Cheung, Walter Hittelman, K. Dane Wittrup, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3628.
Published: 01 May 2009
View articletitled, Abstract #3628: Development and characterization of human anti-CEA single-chain immunotoxins containing rGel: design improvements for greater efficacy
Journal Articles

Abstract #3637: Characterization and mechanistic studies of a novel melanoma-targeting construct containing I \#954; B\#945; to specifically inhibit NF-\#954;B activity

Hong Zhou, Yuying Liu, Lawrence Cheung, Sehoon Kim, Preetha Anand, Bharat Aggarwal, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3637.
Published: 01 May 2009
View articletitled, Abstract #3637: Characterization and mechanistic studies of a novel melanoma-targeting construct containing I \#954; B\#945; to specifically inhibit NF-\#954;B activity
Journal Articles

Abstract #3632: In vitro and in vivo studies of novel recombinant immunotoxins targeting the Her-2/NEU oncogene: Impact of design on biological effects

Yu Cao, James Marks, John Marks, Lawrence Cheung, Sehoon Kim, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3632.
Published: 01 May 2009
View articletitled, Abstract #3632: In vitro and in vivo studies of novel recombinant immunotoxins targeting the Her-2/NEU oncogene: Impact of design on biological effects
Journal Articles

Abstract #2828: A novel fusion construct targeting aggressive tumor cells displaying loss of the tumor suppressor PTEN

Lawrence Cheung, Sehoon Kim, Wei Zhang, Gregg Fuller, John Marks, Yu Cao, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2828.
Published: 01 May 2009
View articletitled, Abstract #2828: A novel fusion construct targeting aggressive tumor cells displaying loss of the tumor suppressor PTEN
Journal Articles

Characterization studies of novel, human anti-CEA immunotoxins containing rGel

Sehoon Kim, Lawrence Cheung, K Wittrup, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4056.
Published: 01 May 2008
View articletitled, Characterization studies of novel, human anti-CEA immunotoxins containing rGel
Journal Articles

The vascular ablative agent VEGF121/rGel targets osteoblast proliferation and inhibits prostate cancer-induced bone formation

Khalid Mohamedali, Zhi Gang Li, Sehoon Kim, Nora Navone, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4093.
Published: 01 May 2007
View articletitled, The vascular ablative agent VEGF121/rGel targets osteoblast proliferation and inhibits prostate cancer-induced bone formation
Journal Articles

Recombinant single-chain antibody fusion protein targeting human melanoma cells and containing BAX pro-apoptotic protein

Sehoon Kim, Michael Rosenblum
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 4891.
Published: 01 May 2007
View articletitled, Recombinant single-chain antibody fusion protein targeting human melanoma cells and containing BAX pro-apoptotic protein
Journal Articles

Identification of the role of VEGF receptors in bone remodeling by the vascular targeting agent VEGF121/rGel

Khalid A. Mohamedali, Ann T. Poblenz, Sehoon Kim, Jun Yang, Nora M. Navone, Philip Thorpe, Bryant Darnay, Michael G. Rosenblum
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 875.
Published: 15 April 2006
View articletitled, Identification of the role of VEGF receptors in bone remodeling by the vascular targeting agent VEGF121/rGel